Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06566209 · ClinicalTrials.gov registry record
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
A clinical trial of Hematologic Malignancy and Myocarditis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06566209: Recruiting study of Hematologic Malignancy and Myocarditis, sponsored by Mayo Clinic.
NCT06566209 is a study of Hematologic Malignancy and Myocarditis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06566209, a study of Hematologic Malignancy and Myocarditis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.
Primary Outcome
Assessed by reviewing 18F-FDG PET/CT imaging for presence of inflammation, progression/regression of inflammation or scarring.
Conditions Studied
Interventions
- DEVICE Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2027-04-30 |
What NCT06566209 shows while recruiting
NCT06566209 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower).
The record links to 7 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) is the first listed.
NCT06566209 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06566209 about?
NCT06566209 is a clinical study titled "FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis". The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically rel...
What is the current status of trial NCT06566209?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-10-11. Estimated completion is 2027-04-30.
What conditions does trial NCT06566209 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Myocarditis, Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, ICI-Myocarditis, Solid Malignant Tumor.
What interventions are being tested in trial NCT06566209?
The interventions under investigation include: Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) (DEVICE).
Who is sponsoring clinical trial NCT06566209?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06566209 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06566209's enrollment target sits among peer trials
30 34th of 48 higher than 11 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI